Trial Profile
A Multicenter, Double-Blind, Randomized, Parallel-Group, Phase III Study of the Efficacy and Safety of Hercules Plus Taxane Versus Herceptin Plus Taxane as First Line Therapy in Patients With HER2-Positive Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Docetaxel; Paclitaxel
- Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms HERITAGE
- Sponsors Mylan
- 01 Jul 2021 In this analysis, efficacy endpoints were reported in all patients who enrolled after the second protocol amendment (intention-to-treat population [ITT]), which excluded patients who had already received first-line therapy.
- 01 Jul 2021 Results reporting final overall survival (OS) from HERITAGE published in the Breast Cancer Research and Treatment
- 02 Dec 2019 According to Mylan N.V media release, Dr. Hope S. Rugo, professor of medicine at the University of California, San Francisco, is lead author of the HERITAGE study